Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;64(1):84-87.
doi: 10.1007/s00108-022-01424-7. Epub 2022 Oct 28.

[Recurrent SARS-CoV-2 infections in immunodeficiency]

[Article in German]
L Tometten  1 , J J Malin  1 , E Pracht  1 , P J Bröckelmann  1 , C Horn  1 , R Sprute  1 , C A Langhorst  2 , M Hallek  1 , G Fätkenheuer  1 , J Rybniker  3
Affiliations

[Recurrent SARS-CoV-2 infections in immunodeficiency]

[Article in German]
L Tometten et al. Inn Med (Heidelb). 2023 Jan.

Abstract
in English, German

A patient with immunodeficiency due to a B-cell lymphoma has repeatedly been tested positive for SARS-CoV‑2 during the ongoing SARS-CoV‑2 pandemic and has twice received in-hospital treatment. Chronic and recurrent SARS-CoV‑2 infections are a threat to the individual health of immunodeficient patients. Only few therapeutic options are available especially due to emerging virus variants with immune escape mechanisms. The medical care of immunodeficient patients with SARS-CoV‑2 infections is a great challenge to the treating physician in the ongoing pandemic.

Ein Patient mit Immundefizienz im Rahmen eines B‑Zell-Lymphoms wurde seit Beginn der SARS-CoV-2-Pandemie wiederholt positiv auf SARS-CoV‑2 getestet und zweimal stationär versorgt. Chronische und rezidivierende SARS-CoV-2-Infektionen gefährden die Gesundheit von Patientinnen und Patienten mit Immundefizienz. Insbesondere aufgrund neuer Virusvarianten mit Immune-escape-Mechanismen sind die Therapieoptionen eingeschränkt. Die Versorgung immundefizienter Patienten mit SARS-CoV-2-Infektion stellt behandelnde Ärztinnen und Ärzte in der aktuellen Pandemie vor große Herausforderungen.

Keywords: Antiviral treatment; B‑cell neoplasia; COVID-19; Immunodeficiency; Monoclonal antibodies.

PubMed Disclaimer

References

    1. Gruell H, Vanshylla K, Korenkov M, et al. Delineating antibody escape from Omicron sublineages. 2022. - PMC - PubMed
    1. (2022) AWMF S3 Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19 – Living Guideline (Stand 09/2022). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF). https://www.awmf.org/leitlinien/detail/ll/113-001LG.html. Zugegriffen: 16. Sept. 2022
    1. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022 doi: 10.1182/blood.2021012251.. - DOI - PMC - PubMed
    1. Lin W-T, Hung S-H, Lai C-C, et al. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials. J Med Virol. 2022;94:2222–2229. doi: 10.1002/jmv.27623. - DOI - PMC - PubMed
    1. Malin JJ, Di Cristanziano V, Horn C, et al. (2021) SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood Adv. 2022;6(5):1580–1584. doi: 10.1182/bloodadvances.2021006655. - DOI - PMC - PubMed

Publication types

Supplementary concepts